All In Biotech

NDA 022285 · Ucb INC

Keppra Xr

Levetiracetam · Oral

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Sep 12, 2008

Approved uses

3

Original approval plus efficacy supplements

Registered trials

261

71 Phase 3, 26 recruiting

FAERS reports

135,017

111,948 serious, 12,113 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 24, 2025.

KEPPRA XR ® is indicated for the treatment of partial-onset seizures in patients 12 years of age and older. KEPPRA XR is indicated for the treatment of partial-onset seizures in patients 12 years of age and older ( 1 )

Mechanism: The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to synaptic vesicle protein SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • KEPPRA XR · LEVETIRACETAM 500MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • KEPPRA XR · LEVETIRACETAM 750MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Levetiracetam" as an intervention, any sponsor and status, largest first.

All 261 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure16,227
  • drug ineffective12,556
  • off label use9,747
  • fatigue5,664
  • somnolence4,247
  • epilepsy4,201
  • convulsion4,079
  • maternal exposure during pregnancy3,821
  • fall3,812
  • headache3,770
  • nausea3,654
  • dizziness3,638

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004515
2005758
2006908
20071,182
20081,356
20092,211
20102,463
20113,071
20124,029
20134,131
20144,698
20156,500
20168,419
20177,673
201810,372
201912,026
20209,949
202110,133
20228,974
20239,610
20249,964
20258,933
20267,138

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Keppra XR (Levetiracetam)

2024 spending

$25.0M

Beneficiaries

1,993

13,615 claims

Per beneficiary

$12,522

$10.38 per unit

View as table
YearSpending
2020$26,749,616
2021$25,351,310
2022$26,257,418
2023$26,668,750
2024$24,955,693

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 772 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.